| Ticker | Status | Jurisdiction | Filing Date | CP Start | CP End | CP Loss | Deadline |
|---|
| Ticker | Case Name | Status | CP Start | CP End | Deadline | Settlement Amt |
|---|
| Ticker | Name | Date | Analyst Firm | Up/Down | Target ($) | Rating Change | Rating Current |
|---|
Bright Green Corporation (NASDAQ:BGXX) ("Bright Green" or the "Company") today announced that it has signed a letter of intent to supply its DEA-approved marijuana extracts and plant-based psychedelics to Benuvia Operations, a FDA registered, DEA licensed and cGMP certified leader in pharmaceutical cannabinoids, as well as psychedelic molecules currently under investigation for clinical use.
This completely homegrown agreement signals Bright Green's ability and commitment to supply US pharmaceutical partners with high quality organic materials. As part of the supply agreement proposed in the LOI, Benuvia intends to leverage Bright Green's unique position to produce Schedule I & II raw materials in full compliance with Good Agricultural and Collection Practices (GACP), Good Manufacturing Practices (GMP), and the DEA, all within the USA, to produce domestically manufactured cGMP pharmaceutical-grade Active Pharmaceutical Ingredients ("APIs") for US and global markets.
Posted In: BGXX
